Related references
Note: Only part of the references are listed.Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade-refractory idiopathic multicentric Castleman disease
David C. Fajgenbaum et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Plasma proteomics identifies a chemokine storm' in idiopathic multicentric Castleman disease
Sheila K. Pierson et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Epidemiology of Castleman Disease
David Simpson
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2018)
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Frits van Rhee et al.
BLOOD (2018)
Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome
Noriko Iwaki et al.
SCIENTIFIC REPORTS (2017)
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease
David C. Fajgenbaum et al.
BLOOD (2017)
Idiopathic multicentric Castleman's disease: a systematic literature review
Amy Y. Liu et al.
LANCET HAEMATOLOGY (2016)
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
Frits van Rhee et al.
LANCET ONCOLOGY (2014)
IL-6-positive classical Hodgkin's lymphoma co-occurring with plasma cell type of Castleman's disease: report of a case
Akihito Momoi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
IL-6: from its discovery to clinical applications
Tadamitsu Kishimoto
INTERNATIONAL IMMUNOLOGY (2010)
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
N Nishimoto et al.
BLOOD (2005)
Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice
A Katsume et al.
CYTOKINE (2002)
Share Paper
